Published in Cancer Sci on April 13, 2015
HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem (2002) 1.38
MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst (2013) 1.31
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer (1998) 1.13
The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol (2012) 1.12
Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol (1999) 1.07
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia (2011) 1.06
Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation. J Immunol (1998) 1.05
The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol (2010) 1.05
Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol (2008) 1.01
HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer (2012) 1.00
The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur J Immunol (2004) 1.00
Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathology (2011) 0.97
Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells. J Biol Chem (2013) 0.95
Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Rep (2007) 0.93
Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology (2013) 0.92
HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol (2012) 0.92
HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells. Curr Pharm Des (2009) 0.90
Definitive high resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele data. Tissue Antigens (2002) 0.90
The role of TCR stimulation and TGF-beta in controlling the expression of CD94/NKG2A receptors on CD8 T cells. Eur J Immunol (2005) 0.90
Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp (Warsz) (2011) 0.89
Height, weight, BMI and ovarian cancer survival. Gynecol Oncol (2012) 0.88
Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol (2010) 0.87
HLA-E polymorphism in patients with nasopharyngeal carcinoma. Tissue Antigens (2004) 0.85
Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med Oncol (2013) 0.84
Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. Ann Hum Genet (2007) 0.84
HLA-E*0101 allele in homozygous state favors severe bacterial infections in sickle cell anemia. Hum Immunol (2007) 0.81
Characterization of HLA-E polymorphism in four distinct populations in Mainland China. Tissue Antigens (2012) 0.79
Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. Pathol Res Pract (2011) 0.79
Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8+ T cells. Ann Hematol (2009) 0.78
[HLA-E molecule induction on the surface of tumor cells protects them from cytotoxic lymphocytes]. Vopr Onkol (2009) 0.78
Infiltrating CTLs are bothered by HLA-E on tumors. Oncoimmunology (2012) 0.78
MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer. Biochem Biophys Res Commun (2016) 0.75